Oral contraceptives linked to bowel disease

Product information for combined oral contraceptives is set to be updated in the wake of research suggesting their use may be linked to increased risk of inflammatory bowel disease.

The TGA is advising health professionals that it is working with sponsors of combined oral contraceptives and hormone replacement therapy to ensure information regarding inflammatory bowel disease is included in their Product Information documents.

In the latest edition of the TGA’s Medicines Safety Update